What’s the current market cap for Oxford Biomedica stock?

Oxford Biomedica (OXB) has a market cap of £726m as of June 15, 2026.

What is the P/E ratio for Oxford Biomedica stock?

The price to earnings (P/E) ratio for Oxford Biomedica (OXB) stock is 0 as of June 15, 2026.

Does Oxford Biomedica stock pay dividends?

No, Oxford Biomedica (OXB) stock does not pay dividends to its shareholders as of June 15, 2026.

When is the next Oxford Biomedica dividend payment date?

Oxford Biomedica (OXB) stock does not pay dividends to its shareholders.

What is the beta indicator for Oxford Biomedica?

Oxford Biomedica (OXB) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Oxford Biomedica stock | £OXB Share Price

07:00

09:10

11:15

13:25

15:30

About Oxford Biomedica

Ticker

£OXB

Sector

Health

Primary listing

LSE

Employees

977

Headquarters

Oxford, United Kingdom

Website

www.oxb.com

Oxford Biomedica Metrics

BasicAdvanced

£726m

-£0.27

1.09

What the Analysts think about Oxford Biomedica

Analyst ratings (Buy, Hold, Sell) for Oxford Biomedica stock.

Bulls say / Bears say

In FY2025, Oxford Biomedica posted 33% constant-currency revenue growth to £170.9 million and achieved an operating EBITDA profit of £8.1 million, marking its first full-year profitability driven by strategic execution and cost control.

As of 31 December 2025, the company’s revenue backlog rose by about 36% to £204 million, while contracted client orders grew 20% to £224 million, ensuring strong visibility into 2026 and early 2027 revenues.

The acquisition of an FDA-approved viral vector facility in Durham, North Carolina, along with a new multi-year commercial supply agreement with Bristol Myers Squibb for CAR-T lentiviral vectors, has significantly expanded Oxford Biomedica’s US manufacturing base and secured high-value partnerships.

Oxford Biomedica warned of a core EBITDA loss in the first half of 2026 due to the timing of revenues, significant technology transfer expenses, and planned maintenance shutdowns, which will shift profitability to the second half.

Despite reporting operating EBITDA profit, the group recorded a loss after tax of £30.6 million for the year ended December 2025, mainly due to substantial non-operating and financing charges.

Shares fell by nearly 10% in late February 2026 after private equity firm EQT withdrew its potential takeover offer, highlighting market doubts about Oxford Biomedica’s valuation and strategic direction.

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

Oxford Biomedica Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Oxford Biomedica Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by London Stock Exchange, through Infront.

Buy £OXB

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Despite reporting operating EBITDA profit, the group recorded a loss after tax of £30.6 million for the year ended December 2025, mainly due to substantial non-operating and financing charges.

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

About Oxford Biomedica

Ticker

Primary listing

Employees

Oxford Biomedica Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Oxford Biomedica

Analyst Ratings

Bulls say / Bears say

Oxford Biomedica Financial Performance

Income Statement

Oxford Biomedica Earnings Performance

Earnings per share (EPS)

Buy £OXB

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Oxford Biomedica/£OXB

About Oxford Biomedica

Ticker

Primary listing

Employees

Oxford Biomedica Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Oxford Biomedica

Analyst Ratings

Bulls say / Bears say

Oxford Biomedica Financial Performance

Income Statement

Oxford Biomedica Earnings Performance

Earnings per share (EPS)

Buy £OXB

Upcoming events

No upcoming events

What’s the current market cap for Oxford Biomedica stock?

What is the P/E ratio for Oxford Biomedica stock?

Does Oxford Biomedica stock pay dividends?

When is the next Oxford Biomedica dividend payment date?

What is the beta indicator for Oxford Biomedica?

Bulls say / Bears say